Biogen (BIIB) Short term Debt (2010 - 2025)

Biogen (BIIB) has reported Short term Debt for 14 consecutive years, with $150.0 million the latest figure, recorded in Q2 2025.

• In Q2 2025, Short term Debt changed N/A year-over-year to $150.0 million; the TTM figure through Jun 2025 stood at $150.0 million (changed N/A YoY), while the FY2024 annual figure was $1.7 billion, up 1065.73% from the prior year.
• Short term Debt came in at $150.0 million for Q2 2025 at Biogen, down from $1.7 billion in the prior quarter.
• The five-year high for Short term Debt was $1.7 billion in Q4 2024, with the low at $150.0 million in Q4 2023.
• Average Short term Debt over 4 years is $761.9 million, with a median of $574.6 million recorded in 2021.
• The largest YoY upside for Short term Debt was 1065.73% in 2024 against a maximum downside of 1065.73% in 2024.
• Year by year, Short term Debt stood at $999.1 million in 2021, then slumped by 84.99% to $150.0 million in 2023, then jumped by 1065.73% to $1.7 billion in 2024, then sank by 91.42% to $150.0 million in 2025.
• According to Business Quant data, Short term Debt over the past three periods registered $150.0 million, $1.7 billion, and $150.0 million for Q2 2025, Q4 2024, and Q4 2023 respectively.